Lundbeck earned $51.7M in settlements with generic makers over Lexapro patent
Intellectual Property 2019-02-27 10:09 pm By Christine Caulfield | Melbourne
Please login to bookmark Close

Danish pharmaceutical giant Lundbeck secured $51.7 million in settlements to end infringement litigation with three generic makers over its patent for the top-selling Lexapro, the company has revealed.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au